Psychedelic substitution: altered substance use patterns following psychedelic use in a global survey.

"Conflict of interest KB has received grant funding from Tryp Therapeutics for a clinical trial of psilocybin-assisted therapy and sits on a data safety and monitoring board for an ongoing clinical trial with Vireo Health unpaid. PL is President of SABI Mind, one of the co-sponsors of the study. NG owns stock in Cybin Inc., Mind Medicine Inc., Numinus Wellness, Revive Therapeutics, Braxia Scientific, and Compass Pathways. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest."

"The author(s) declare financial support was received for the research, authorship, and/or publication of this article. The Global Psychedelic Survey was co-sponsored by the Multidisciplinary Association of Psychedelic Studies (MAPS), Mind Medicine Australia, Tiny, and SABI Mind. These funds were used to cover the cost of the data capture system provided by Quantified Citizen and associated programming, as well as the initial data coding/cleaning and analysis conducted by Precision Analytics."